The role of aromatase inhibitors in the treatment of metastatic breast cancer

被引：23

作者：

Mouridsen, H

Gershanovich, M

机构：

[1] Rigshosp, Dept Oncol, Finsen Ctr, DK-2100 Copenhagen, Denmark

[2] NN Petrov Oncol Res Inst, Dept Clin Oncol, St Petersburg, Russia

来源：

SEMINARS IN ONCOLOGY | 2003年 / 30卷 / 04期

关键词：

D O I：

10.1016/S0093-7754(03)00301-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：33 / 45

页数：13

共 35 条

[21] Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial [J].

Kaufmann, M ;

Bajetta, E ;

Dirix, LY ;

Fein, LE ;

Jones, SE ;

Zilembo, N ;

Dugardyn, JC ;

Nasurdi, C ;

Mennel, RG ;

Cervek, J ;

Fowst, C ;

Polli, A ;

di Salle, E ;

Arkhipov, A ;

Piscitelli, G ;

Miller, LL ;

Massimini, G .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (07) :1399-1411

[22] Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial [J].

Lonning, PE ;

Bajetta, E ;

Murray, R ;

Tubiana-Hulin, M ;

Eisenberg, PD ;

Mickiewicz, E ;

Celio, L ;

Pitt, P ;

Mita, M ;

Aaronson, NK ;

Fowst, C ;

Arkhipov, A ;

di Salle, E ;

Polli, A ;

Massimini, G .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (11) :2234-2244

[23] Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer:: Results of a phase III study of the international letrozole breast cancer group [J].

Mouridsen, H ;

Gershanovich, M ;

Sun, Y ;

Pérez-Carrión, R ;

Boni, C ;

Monnier, A ;

Apffelstaedt, J ;

Smith, R ;

Sleeboom, HP ;

Jänicke, F ;

Pluzanska, A ;

Dank, M ;

Becquart, D ;

Bapsy, PP ;

Salminen, E ;

Snyder, R ;

Lassus, M ;

Verbeek, JA ;

Staffler, B ;

Chaudri-Ross, HA ;

Dugan, M .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) :2596-2606

[24] Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:: Analysis of survival and update of efficacy from the international letrozole breast cancer group [J].

Mouridsen, H ;

Gershanovick, M ;

Sun, Y ;

Pérez-Carrión, R ;

Boni, C ;

Monnier, A ;

Apffelstaedt, J ;

Smith, R ;

Sleeboom, HP ;

Jaenicke, F ;

Pluzanska, A ;

Dank, M ;

Becquart, D ;

Bapsy, PP ;

Salminen, E ;

Snyder, R ;

Chaudri-Ross, H ;

Lang, R ;

Wyld, P ;

Bhatnagar, A .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (11) :2101-2109

[25] Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial [J].

Nabholtz, JM ;

Buzdar, A ;

Pollak, M ;

Harwin, W ;

Burton, G ;

Mangalik, A ;

Steinberg, M ;

Webster, A ;

von Euler, M .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (22) :3758-3767

[26]

Pyrhönen S, 1999, BREAST CANCER RES TR, V56, P133

[27] FACTORS PREDICTING THE RESPONSE OF PATIENTS WITH ADVANCED BREAST-CANCER TO ENDOCRINE (MEGACE) THERAPY [J].

ROBERTSON, JFR ;

WILLIAMS, MR ;

TODD, J ;

NICHOLSON, RI ;

MORGAN, DAL ;

BLAMEY, RW .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (03) :469-475

[28]

Robertson WR, 1997, STUD PROFERLIT, V6, P33

[29]

ROSE C, 2002, P AN M AM SOC CLIN, V21, pA34

[30]

Roseman BJ, 1997, J SURG ONCOL, V66, P215, DOI 10.1002/(SICI)1096-9098(199711)66:3<215::AID-JSO11>3.3.CO

← 1 2 3 4 →